The Latest: Trump unveils deal to lower costs on obesity drugs Updated 8 mins ago President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years. Access to the drugs has been limited because of their costs and spotty insurance coverage. The administration said Thursday coverage of the drugs for obesity will expand to Medicare patients starting next year, and some lower prices also will be phased in for patients without coverage.

See Full Page